Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2008 1
2009 2
2010 1
2011 2
2012 1
2014 1
2015 5
2016 1
2017 4
2018 6
2019 2
2020 5
2021 4
2022 5
2023 6
2024 4
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of so …
In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, …
The Role of Interferon-gamma in Autoimmune Polyendocrine Syndrome Type 1.
Oikonomou V, Smith G, Constantine GM, Schmitt MM, Ferré EMN, Alejo JC, Riley D, Kumar D, Dos Santos Dias L, Pechacek J, Hadjiyannis Y, Webb T, Seifert BA, Ghosh R, Walkiewicz M, Martin D, Besnard M, Snarr BD, Deljookorani S, Lee CR, DiMaggio T, Barber P, Rosen LB, Cheng A, Rastegar A, de Jesus AA, Stoddard J, Kuehn HS, Break TJ, Kong HH, Castelo-Soccio L, Colton B, Warner BM, Kleiner DE, Quezado MM, Davis JL, Fennelly KP, Olivier KN, Rosenzweig SD, Suffredini AF, Anderson MS, Swidergall M, Guillonneau C, Notarangelo LD, Goldbach-Mansky R, Neth O, Monserrat-Garcia MT, Valverde-Fernandez J, Lucena JM, Gomez-Gila AL, Garcia Rojas A, Seppänen MRJ, Lohi J, Hero M, Laakso S, Klemetti P, Lundberg V, Ekwall O, Olbrich P, Winer KK, Afzali B, Moutsopoulos NM, Holland SM, Heller T, Pittaluga S, Lionakis MS. Oikonomou V, et al. N Engl J Med. 2024 May 30;390(20):1873-1884. doi: 10.1056/NEJMoa2312665. N Engl J Med. 2024. PMID: 38810185 Free PMC article.
BACKGROUND: Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune regulator (AIRE) deficiency. In APS-1, self-reactive T cells escape thymic negative selection, infiltrate organs, and drive autoi …
BACKGROUND: Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimm …
Low-dose naltrexone for treatment of dermatologic conditions: A clinical review.
Zhou MH, Elston DM, Morrison BW, Lipner SR. Zhou MH, et al. J Am Acad Dermatol. 2026 Jan;94(1):200-207. doi: 10.1016/j.jaad.2025.09.028. Epub 2025 Sep 15. J Am Acad Dermatol. 2026. PMID: 40962192 Review.
Naltrexone is a long-acting opioid receptor antagonist that may be compounded at lower doses (1-5 mg) to treat inflammatory or autoimmune conditions. Low-dose naltrexone (LDN) transiently blocks the opioid receptor, resulting in increased ligand and receptor express …
Naltrexone is a long-acting opioid receptor antagonist that may be compounded at lower doses (1-5 mg) to treat inflammatory or autoimmune …
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.
Löhn M, Wirth KJ. Löhn M, et al. J Transl Med. 2024 Jul 5;22(1):630. doi: 10.1186/s12967-024-05412-3. J Transl Med. 2024. PMID: 38970055 Free PMC article. Review.
Dysfunction of TRPM3 in natural killer (NK) cells, characterized by reduced calcium flux, has been observed in ME/CFS and PCS patients, suggesting a role in ineffective pathogen clearance and potential virus persistence and autoimmunity development. TRPM3 dysfunction in NK …
Dysfunction of TRPM3 in natural killer (NK) cells, characterized by reduced calcium flux, has been observed in ME/CFS and PCS patients, sugg …
Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Liu WM, Dalgleish AG. Liu WM, et al. Expert Rev Anticancer Ther. 2022 Mar;22(3):269-274. doi: 10.1080/14737140.2022.2037426. Epub 2022 Feb 7. Expert Rev Anticancer Ther. 2022. PMID: 35107043 Free article. Review.
This group of patients had chronic inflammatory and autoimmune conditions and reported improvements whilst using the lower dosages of naltrexone. ...EXPERT OPINION: Considering the increase in the number of anecdotal reports of activity, there will likely be a bigger drive …
This group of patients had chronic inflammatory and autoimmune conditions and reported improvements whilst using the lower dosages of …
Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS, McLaughlin PJ. Zagon IS, et al. Exp Biol Med (Maywood). 2018 Dec;243(17-18):1323-1330. doi: 10.1177/1535370218817746. Epub 2018 Dec 12. Exp Biol Med (Maywood). 2018. PMID: 30541348 Free PMC article. Review.
This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose naltrexone (LDN), and the role of enkephalin (i.e. OGF) in autoimmune disorders, specifically multiple sclerosis, Crohn's, and f …
This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose na …
Low-Dose Naltrexone in Rheumatological Diseases.
de Carvalho JF, Skare T. de Carvalho JF, et al. Mediterr J Rheumatol. 2023 Mar 31;34(1):1-6. doi: 10.31138/mjr.34.1.1. eCollection 2023 Mar. Mediterr J Rheumatol. 2023. PMID: 37223594 Free PMC article. Review.
BACKGROUND: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders. ...METHODS: PubMed and Embase databases …
BACKGROUND: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in sever …
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Rahn KA, McLaughlin PJ, Zagon IS. Rahn KA, et al. Brain Res. 2011 Mar 24;1381:243-53. doi: 10.1016/j.brainres.2011.01.036. Epub 2011 Jan 20. Brain Res. 2011. PMID: 21256121
Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met(5)]-enkephalin) and a low dose of the opioid antagonist naltre …
Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30days of treatment. Thi …
Pseudo-endocrine Disorders: Recognition, Management, and Action.
McDermott MT. McDermott MT. J Endocr Soc. 2024 Dec 17;9(1):bvae226. doi: 10.1210/jendso/bvae226. eCollection 2024 Nov 26. J Endocr Soc. 2024. PMID: 39749108 Free PMC article.
Hypogonadism ("low T") is frequently diagnosed in "men's health" clinics and other venues without actual hormone testing or further evaluation and is often treated with supraphysiologic testosterone therapy that suppresses endogenous gonadal testosterone and sperm production, lea …
Hypogonadism ("low T") is frequently diagnosed in "men's health" clinics and other venues without actual hormone testing or further evaluati …
[Met5]-enkephalin preserves diffusion metrics in EAE mice.
Patel C, Meadowcroft MD, Zagon IS, McLaughlin PJ. Patel C, et al. Brain Res Bull. 2020 Dec;165:246-252. doi: 10.1016/j.brainresbull.2020.10.015. Epub 2020 Oct 24. Brain Res Bull. 2020. PMID: 33141073
This research investigated whether non-invasive imaging correlated with animal behavior and morphological indicators of disease in response to serum levels of [Met(5)]-enkephalin. Using the experimental autoimmune encephalomyelitis (EAE) model, adult female C57BL/6 J mice …
This research investigated whether non-invasive imaging correlated with animal behavior and morphological indicators of disease in response …
53 results